(Q37575533)

21 August 2017

1 reference

title

The economic implications of generic substitution of antiepileptic drugs: a review of recent evidence (English)

1 reference

21 August 2017

Mei Sheng Duh

1

1 reference

21 August 2017

Kevin E Cahill

2

1 reference

21 August 2017

Pierre Emmanuel Paradis

3

1 reference

21 August 2017

Pierre Y Cremieux

4

1 reference

21 August 2017

Paul E Greenberg

5

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 October 2009

1 reference

Expert Opinion on Pharmacotherapy

21 August 2017

published in

1 reference

21 August 2017

volume

10

1 reference

21 August 2017

issue

14

1 reference

21 August 2017

page(s)

2317-2328

1 reference

Are there potential problems with generic substitution of antiepileptic drugs? A review of issues

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140525

Clinical consequences of generic substitution of lamotrigine for patients with epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140525

Current approaches to the use of generic antiepileptic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140525

Generic antiepileptic drugs: current controversies and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140525

The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140525

Generic drugs. Therapeutic equivalence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140525

Bioequivalence and other unresolved issues in generic drug substitution

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140525

The economic cost of epilepsy: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140525

The use of antiepileptic drugs--principles and practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140525

Combination therapy in epilepsy: when and what to use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140525

Generic equivalents: issues and concerns

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140525

Is generic prescribing acceptable in epilepsy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140525

Steady-state pharmacokinetics of lamotrigine when converting from a twice-daily immediate-release to a once-daily extended-release formulation in subjects with epilepsy (The COMPASS Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140525

Comparison of steady-state blood levels of two carbamazepine formulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140525

Prescribing antiepileptic drugs: should patients be switched on the basis of cost?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140525

Cost of refractory epilepsy in adults in the USA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140525

Antiepileptic drugs: generic versus branded treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140525

10.1517/14656560903140525

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference